Shibata Takeo, Makinoda Satoru, Waseda Tomoo, Tomizawa Hideki, Fujii Ryota, Utsunomiya Takafumi
Department of Obstetrics and Gynecology, Kanazawa Medical University, Uchinada, Japan.
Department of Obstetrics and Gynecology, Kanazawa Medical University, Uchinada, Japan.
Transl Res. 2016 May;171:63-70. doi: 10.1016/j.trsl.2015.10.003. Epub 2015 Oct 23.
Luteinized unruptured follicle (LUF) syndrome is one of the intractable ovulation disorders that are commonly observed during cycles of treatment with ovulation inducers, for which no effective therapy other than assisted reproductive technology is available. Here, we investigated whether granulocyte colony-stimulating factor (G-CSF) could prevent the onset of LUF syndrome. We analyzed the effects of G-CSF in 68 infertile women with LUF syndrome who received ovulation induction (clomiphene + human chorionic gonadotropin [hCG] therapy or follicle-stimulating hormone + hCG therapy). G-CSF (lenograstim, 100 μg) was administered subcutaneously. Onsets of LUF syndrome were compared between the cycle during which G-CSF was given in combination with the ovulation inducer (ie, the G-CSF treatment cycle) and the subsequent cycle during which only the ovulation inducer was given (ie, the G-CSF nontreatment control cycle). The results showed that LUF syndrome recurred in only 3 cycles during the G-CSF treatment cycle (4.4% [3/68 cycles]), whereas LUF syndrome recurred in 13 cycles during the subsequent G-CSF nontreatment control cycle (19.1% [13/68 cycles]). The additional use of G-CSF significantly prevented the onset of LUF syndrome during ovulation induction (P = 0.013, McNemar test). No serious adverse reactions because of the administration of G-CSF were observed. In conclusion, our findings indicate that G-CSF may become a useful therapy for LUF syndrome.
黄素化未破裂卵泡(LUF)综合征是排卵诱导治疗周期中常见的难治性排卵障碍之一,除辅助生殖技术外,尚无有效的治疗方法。在此,我们研究了粒细胞集落刺激因子(G-CSF)是否能预防LUF综合征的发生。我们分析了G-CSF对68例接受排卵诱导(克罗米芬+人绒毛膜促性腺激素[hCG]治疗或促卵泡激素+hCG治疗)的LUF综合征不孕妇女的影响。皮下注射G-CSF(来格司亭,100μg)。比较了G-CSF与排卵诱导剂联合使用的周期(即G-CSF治疗周期)和随后仅使用排卵诱导剂的周期(即G-CSF非治疗对照周期)中LUF综合征的发生率。结果显示,G-CSF治疗周期中仅3个周期出现LUF综合征复发(4.4%[3/68个周期]),而在随后的G-CSF非治疗对照周期中有13个周期出现LUF综合征复发(19.1%[13/68个周期])。额外使用G-CSF可显著预防排卵诱导期间LUF综合征的发生(P = 0.013,McNemar检验)。未观察到因使用G-CSF而出现的严重不良反应。总之,我们的研究结果表明,G-CSF可能成为治疗LUF综合征的有效方法。